Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Novartis acquires Hexal, Eon Labs for €5.65bn

Executive Summary

Novartis has agreed to acquire two generics companies for €5.65bn ($7.38bn) in cash--67.7% of Eon Labs for €1.3bn and 100% of Hexal AG, Eon's parent company, for €4.35bn. Novartis plans to buy the remainder of Eon via a tender offer of €23.73 per share (a 25% premium to Eon's trading price before the market was affected by take-over speculation).
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Contract
    • Payment Includes Cash

Related Companies